Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Clinical Application of $^{18}F-FDG$ PET in Alzheimer's Disease

알쯔하이머병(Alzheimer's disease)에서 FDG PET의 임상이용

  • Ryu, Young-Hoon (Division of Nuclear Medicine, Department of Diagnostic Radiology, Yonsei University College of Medicine)
  • 유영훈 (연세대학교 의과대학 영상의학교실 핵의학과)
  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

PET of the cerebral metabolic rate of glucose is increasingly used to support the clinical diagnosis in the examination of patients with suspected major neurodegenerative disorders, such as Alzheimer's disease. $^{18}F-FDG$ PET has been reported to have high diagnostic performance, especially, very high sensitivity in the diagnosis and clinical assessment of therapeutic efficacy. According to clinical research data hitherto, $^{18}F-FDG$ PET is expected to be an effective diagnostic tool in early and differential diagnosis of Alzheimer's disease. Since 2004, Medicare covers $^{18}F-FDG$ PET scans for the differential diagnosis of fronto-temporal dementia (FTD) and Alzheimer's disease (AD) under specific requirements; or, its use in a CMS approved practical clinical trial focused on the utility of $^{18}F-FDG$ PET in the diagnosis or treatment of dementing neurodegenerative diseases.

Keywords